Primärquellen-Eintrag
EntscheidungsrelevantTopline-Ergebnisse
Arcturus: Zwischenanalyse der Phase-2-Studie zu ARCT-032 zeigt Schleimreduktion bei Mukoviszidose der Klasse I
Interim Phase 2 data from six Class I CF adults treated with 10 mg ARCT-032 for 28 days showed mucus plug and volume reductions in four of six participants on AI-enhanced HRCT. Exploratory FEV1 analysis suggested directional lung-function improvement. The company plans to start a 12-week safety and preliminary efficacy study in up to 20 CF participants in the first half of 2026.
Kernfakten
- Eingereicht
- 22. Okt. 2025, 11:50
- Ereignis
- Topline-Ergebnisse
- Richtung
- Positiv
- Unternehmen
ARCTArcturus Therapeutics- Asset
- ARCT-032
- Quelle
- SEC 8-K
- Belegstatus
- Belegt
- ppFEV1-Anstieg
- 3.8% absolut, 5.1% relativ (exploratorisch)
- Mukoviszidose-Pfropfen-Reduktion
- 4/6 Teilnehmer
- Schleimvolumen-Reduktion
- 4/6 Teilnehmer
Auszug aus der Quelle
EX-99.1 2 e664913_ex99-1.htm EX-99.2 3 e664913_ex99-2.htm Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program ARCT-032 generally safe and well tolerated Meaningful trends of clinical activity observed via high resolution CT scans After only 28 days of treatment with ARCT-032 (10 mg), 4 out of 6 Class I CF participants exhibited encouraging reduction of mucus plug number and mucus volume 12-week study enrolling up to 20 CF participants planned to begin first half of 2026 SAN DIEGO--(BUSINESS WIRE)—Oct 21, 2025-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics and infectious disease vaccines, today an